Inclusion Criteria:

          -  Patients must have histologically documented or cytologically confirmed Hodgkin
             lymphoma; confirmation must include CD30 expression

          -  Patients must be either refractory to or relapsed after only induction therapy;
             patients who do not achieve CR after induction therapy are considered primary
             refractory and are allowed to enter study

          -  > 40 kg

          -  Absolute neutrophil count (ANC) >= 1500/uL; filgrastim can be given before and during
             treatment to achieve target ANC >= 1500 uL

          -  Platelet (Plt) >= 75,000/uL

          -  Hemoglobin >= 8.5 g/dl

          -  Platelet transfusion and packed red blood cell transfusion can also be given prior to
             the start of treatment and treatment to achieve a target plt >= 75,000/uL and
             hemoglobin of >= 8.5 g/dl, provided that patients have not received growth factors for
             at least 14 days prior to entering trial

          -  Patients must have measurable disease > 1.5 cm evidenced by computed tomography (CT)
             scan of the neck/chest/abdomen/pelvis or CT/positron emission tomography (PET) scans

          -  Life expectancy of greater than 3 months

          -  Eastern Cooperative Oncology Group (ECOG) of 0-2

          -  Documented informed consent/assent of the participant or legally responsible guardian

          -  Diffusion capacity of the lung for carbon monoxide (DLCO) >= 60%

          -  Total bilirubin with 1.5 x the upper limit of normal (ULN) institutional limits;
             patients with elevation of unconjugated bilirubin alone, as in Gilbert's disease, are
             eligible

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x the
             institutional upper limit of normal (unless demonstrated Hodgkin lymphoma involvement
             of the liver); estimated creatinine clearance >= 30 ml/min (Cockcroft-Gault) and/or 24
             urine analysis as needed

          -  For patients with Hodgkin lymphoma (HL) involvement of the liver, AST/ALT < 5.0 x
             institutional ULN; total bilirubin within 3.0 x institutional ULN; (although patients
             with HL involvement of the liver are frequently excluded from trials, their liver
             function tests often improve after treatment; the studies that led to nivolumab
             approval did not reveal any increased signals of liver toxicities attributed to
             nivolumab)

          -  Prothrombin time (PT)/international normalized ration (INR) < 1.5 x ULN and partial
             thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN

          -  Female subject is either post-menopausal, surgically sterilized, or willing to use and
             acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine
             device, diaphragm with spermicide, condom with spermicide, or abstinence) for the
             duration of the study; women of childbearing potential (WOCBP) must have a negative
             serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG)
             within 24 hours prior to the start of nivolumab

          -  Men who are sexually active with WOCBP must use any contraceptive method with a
             failure rate of less than 1% per year; men receiving nivolumab and who are sexually
             active with WOCBP will be instructed to adhere to contraception for a period of 31
             weeks after the last dose of investigational product; women who are not of
             childbearing potential (i.e., who are postmenopausal or surgically sterile) as well as
             azoospermic men do not require contraception

          -  All participants will undergo standard written informed consent procedures as dictated
             by the City of Hope Human Research Protections Office prior to performing any
             screening procedures that are not part of standard-of-care; informed consent will be
             obtained by the principal investigator, collaborating investigators, or other
             Institutional Review Board (IRB) designated personnel who will meet the training
             requirements established by the IRB; with the support of research personnel, he/she
             will explain the nature, duration, purpose of the study, potential risks, alternatives
             and potential benefits, and all other information contained in the informed consent
             document; in addition, they will review the experimental subject's bill of rights and
             the Health Insurance Portability and Accountability Act (HIPAA) research authorization
             form; prospective research participants will be informed that they may withdraw from
             the study at any time and for any reason without prejudice; prospective research
             participants will be afforded sufficient time to consider whether or not to
             participate in the research

          -  Patient must be either refractory to or relapsed after 1 line of therapy; prior
             radiation therapy is allowed

          -  INCLUSION CRITERIA FOR COHORT B:

          -  B symptoms at relapse

          -  Extranodal disease at relapse

          -  Primary refractory disease

          -  Relapsed < 1 year after completion of frontline therapy

          -  Have received brentuximab vedotin as initial therapy

        Exclusion Criteria:

          -  Prior exposure to PD-1 or PD-L1 inhibitors is not allowed

          -  Must not have had second line chemotherapy for Hodgkin lymphoma

          -  Active autoimmune diseases requiring systemic treatments

          -  Vaccinated with live, attenuated vaccine within 4 weeks of first dose of study drug

          -  Any life-threatening illness, medical condition, or organ system dysfunction that, in
             the investigator's opinion, could compromise the subject's safety or put the study
             outcomes at undue risk

          -  Unwilling or unable to participate in all required study evaluations and procedures

          -  Unable to understand the purpose and risks of the study and to provide a signed and
             dated informed consent for (ICF) and authorization to use protected health information
             (in accordance with national and local subject privacy regulations)

          -  Patients should not have any uncontrolled illness including ongoing or active
             infection

          -  Patients may not be receiving any other investigational agents, or concurrent
             biological therapy, chemotherapy, or radiation therapy

          -  Patients must not have received prior chemotherapy or radiation for =< 3 weeks before
             study enrollment, or those who have not recovered from the adverse events due to
             agents administered more than 3 weeks earlier are excluded

          -  Myocardial infarction within 6 months prior to enrollment or New York Heart
             Association (NYHA) class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities; prior study entry, any
             electrocardiogram (ECG) abnormality at screening has to be documented by the
             investigator as not medically relevant

          -  Significant screening electrocardiogram (ECG) abnormalities including, but not limited
             to, left bundle branch block, 2nd degree atrioventricular (AV) block type II, 3rd
             degree block, or corrected QT interval (QTc) >= 470 msec; subjects with a cardiac
             pacemaker who have a QTc interval of >= 470 msec may be eligible if these findings are
             considered not clinically significant as documented via a cardiology evaluation

          -  DLCO < 60%; the clinical studies in support of accelerated approval for nivolumab in
             chronic (c)HL after failure of ASCT required DLCO > 60%; certain HL induction regimens
             have the potential for pulmonary toxicity, and nivolumab carries the potential of
             pneumonitis or other pulmonary toxicities

          -  Diagnosed or treated for another malignancy within 3 years of enrollment, with the
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy

          -  Patients with active central nervous system (CNS) disease or history of brain
             metastases are excluded from study

          -  Patients should be excluded if they have a condition requiring systemic treatment with
             either corticosteroids (> 10 mg daily prednisone equivalents) or other
             immunosuppressive medications within 14 days of study drug administration; inhaled or
             topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents
             are permitted in the absence of active autoimmune disease

          -  Pregnant women are excluded from this study because of the potential for teratogenic
             or abortifacient effects; because there is an unknown but potential risk of adverse
             events in nursing infants secondary to treatment of the mother, breastfeeding should
             be discontinued

          -  Recent infection requiring systemic treatment that was completed =< 14 days before the
             first dose of study drug

          -  Known history of human immunodeficiency virus (HIV), hepatitis C virus (HCV) or
             hepatitis B virus (HBV) infection; subjects who are positive for hepatitis B core
             antibody or hepatitis B surface antigen must have a negative polymerase chain reaction
             (PCR) result before enrollment, those who are PCR positive will be excluded; subjects
             who have an undetectable HIV viral load with CD4 >= 300 and are on highly active
             antiretroviral therapy (HAART) medication are allowed; previously treated hepatitis C
             patients are also allowed; as there is potential for hepatic toxicity with nivolumab
             or nivolumab/ipilimumab combinations, drugs with a predisposition to hepatoxicity
             should be used with caution in patients treated with nivolumab-containing regimen

          -  History of allergy or adverse drug reaction to study components